Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum

Gut

Volumn 61, Issue 6, 2012, Pages 847-854

  Yamauchi, Mai ^a   Morikawa, Teppei ^a   Kuchiba, Aya ^a   Imamura, Yu ^a   Qian, Zhi Rong ^a   Nishihara, Reiko ^a   Liao, Xiaoyun ^a   Waldron, Levi ^a,b   Hoshida, Yujin ^c   Huttenhower, Curtis ^b   Chan, Andrew T ^d,e   Giovannucci, Edward ^b,e   Fuchs, Charles ^a,e   Ogino, Shuji ^a,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANATOMICAL VARIATION; ARTICLE; ASCENDING COLON; BRAF GENE; CANCER LOCALIZATION; CECUM; CLINICAL FEATURE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DESCENDING COLON; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; KRAS GENE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; PHENOTYPE; PIK3CA GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM; SIGMOID; TRANSVERSE COLON; UNITED STATES;

AGED; CECAL NEOPLASMS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; MICROSATELLITE INSTABILITY; MUTATION; MUTATION RATE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECTAL NEOPLASMS; SIGMOID NEOPLASMS;

EID: 84860589077     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300865     Document Type: Article

References (57)

1. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779-88. (Pubitemid 20369667)
2. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;101:403-8.
3. Gervaz P, Bucher P, Morel P. Two colons e two cancers: paradigm shift and clinical implications. J Surg Oncol 2004;88:261-6. (Pubitemid 39601269)
4. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
5. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116-29.
6. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010;138:2088-100.
7. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681-6. (Pubitemid 29354851)
8. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55:1000-6. (Pubitemid 43962613)
9. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93. (Pubitemid 43980599)
10. Yagi K, Akagi K, Hayashi H, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 2010;16:21-33.
11. Hughes LA, Simons CC, van den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One 2011;6:e18571.
12. Zlobec I, Bihl M, Foerster A, et al. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol 2011;225:336-43.
13. Dahlin AM, Palmqvist R, Henriksson ML, et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010;16:1845-55.
14. Tanaka N, Huttenhower C, Nosho K, et al. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol 2010;177:2731-40.
15. Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012;22:271-82.
16. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008;268:177-86.
17. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Pathol Res Int 2011;2011:902674.
18. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008;3:e3698.
19. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-45. (Pubitemid 41242676)
20. Barault L, Charon-Barra C, Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008;68:8541-6.
21. Wong JJ, Hawkins NJ, Ward RL, et al. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Mod Pathol 2011;24:396-411.
22. van Engeland M, Derks S, Smits KM, et al. Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 2011;29:1382-91.
23. Ang PW, Loh M, Liem N, et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 2010;10:227.
24. Slattery ML, Curtin K, Wolff RK, et al. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum 2009;52:1304-11.
25. Minoo P, Zlobec I, Peterson M, et al. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol 2010;37:707-18.
26. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009;136:65-80.
27. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42. (Pubitemid 47010839)
28. Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011;305:1685-94.
29. Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008;100:1734-8.
30. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
31. Ogino S, Kawasaki T, Kirkner GJ, et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006;8:582-8. (Pubitemid 44774157)
32. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-21. (Pubitemid 41149657)
33. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-41. (Pubitemid 351770297)
34. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
35. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-17. (Pubitemid 43811244)
36. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007;9:305-14. (Pubitemid 47305066)
37. Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008;122:2767-73. (Pubitemid 351631379)
38. Irahara N, Nosho K, Baba Y, et al. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn 2010;12:177-83.
39. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
40. Khashab MA, Pickhardt PJ, Kim DH, et al. Colorectal anatomy in adults at computed tomography colonography: normal distribution and the effect of age, sex, and body mass index. Endoscopy 2009;41:674-8.
41. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008;10:13-27. (Pubitemid 351184831)
42. Ibrahim AE, Arends MJ, Silva AL, et al. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut 2011;60:499-508.
43. Schernhammer ES, Giovannucci E, Kawasaki T, et al. Dietary folate, alcohol, and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut 2010;59:794-9.
44. Svrcek M, Buhard O, Colas C, et al. Methylation tolerance due to an O6- methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. Gut 2010;59:1516-26.
45. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 2011;11:9-20.
46. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology e analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8:711-19.
47. Konishi K, Shen L, Jelinek J, et al. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila) 2009;2:814-22.
48. Nosho K, Kure S, Irahara N, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 2009;137:1609-20 e1-3.
49. Gonzalo V, Lozano JJ, Munoz J, et al. Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PLoS One 2010;5:e8777.
50. Norrie MW, Hawkins NJ, Todd AV, et al. The role of hMLH1 methylation in the development of synchronous sporadic colorectal carcinomas. Dis Colon Rectum 2002;45:674-80. (Pubitemid 34507244)
51. Worthley DL, Whitehall VL, Buttenshaw RL, et al. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 2010;29:1653-62.
52. Berggren S, Gall C, Wollnitz N, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007;4:252-7. (Pubitemid 46640601)
53. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003;52:759-66. (Pubitemid 36528884)
54. Mochida Y, Taguchi K, Taniguchi S, et al. The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polyp formation in Apc(Min/+) mice. Carcinogenesis 2003;24:1219-24. (Pubitemid 36927062)
55. Potocnik U, Glavac D, Dean M. Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet Cytogenet 2008;183:28-34. (Pubitemid 351636126)
56. Kucherlapati MH, Yang K, Fan K, et al. Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon. Proc Natl Acad Sci U S A 2008;105:15493-8.
57. Cui X, Shirai Y, Wakai T, et al. Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 2004;35:1189-95. (Pubitemid 39361641)